Working for customers it could not have served a year ago: the company's deliverable capability just stepped up a class
The model's full reasoning — Q4 2022 call → NOWe need to determine if management conveys a capability step-change with all three elements. Let's analyze the transcript. Key points: MRD business, clonoSEQ volumes growing, sales team doubled, launched DLBCL, Epic integration. Immune Medicine: pharma services growth, drug discovery with Genentech. The question asks: "On this call, does management convey that the company CAN NOW ACTUALLY DO SOMETHING — produce, deliver, serve, handle, or perform at a scale, specification, quality, or complexity — that it COULD NOT DO ROUGHLY A YEAR AGO, and that REAL CUSTOMERS ARE ALREADY PAYING FOR THAT NEW CAPABILITY NOW, with the business it enables still early?" We need to find a specific capability step-change with before/after, paying work, and early stage. Look for contrasts. For example, in MRD: "we launched clonoSEQ and DLBCL" - that's a new indication. But is that a capability step-change? It's a new test for a new disease. But is it something they couldn't do before? They had the platform, but now they have a validated test for DLBCL. However, is there paying work? They say "We anticipate DLBCL to be a meaningful contributor in the second half of 2023." So it's not yet paying? Actually they launched at ASH in December, so maybe some early orders? But they say "anticipate" meaning future. So that might not be proven paying work yet. Another: "signed an agreement with Epic for EMR integration" - that's a capability to order via EMR, but not yet integrated? They say "Epic integration which are expected in the back half of the year." So not yet. What about the sales team doubling? That's not a capability step-change in what they can do, but more of a scale of sales effort. Immune Medicine: "Pharma services had substantial growth of 67% versus 2021." That's growth, but is there a new capability? They mention "we delivered two additional shared TCR data packages for Genentech's consideration." That's a capability to deliver data packages, but they already had that. The personalized program: "we successfully identified and characterized T cell receptors to patients specific tumor mutations.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| HCKT | The Hackett Group, Inc. | Q1 2024 | 2024-05-08 | C |
| LINC | Lincoln Educational Services Corporation | Q1 2024 | 2024-05-06 | B+ |
| HUYA | HUYA Inc. | Q4 2023 | 2024-03-19 | C |
| PUMP | ProPetro Holding Corp. | Q4 2023 | 2024-02-21 | C+ |
| SANG | Sangoma Technologies Corporation | Q2 2024 | 2024-02-08 | D |
| OPAD | Offerpad Solutions Inc. | Q3 2023 | 2023-11-01 | C |
| TGLS | Tecnoglass Inc. | Q2 2023 | 2023-08-08 | A |
| CARS | Cars.com Inc. | Q1 2023 | 2023-05-06 | B |
| TSSI | TSS, Inc. | Q4 2022 | 2023-04-03 | D |
| TACT | TransAct Technologies Incorporated | Q4 2022 | 2023-03-08 | A |
| M | Macy's, Inc. | Q4 2022 | 2023-03-02 | D |
| CEIX | CONSOL Energy Inc. | Q4 2022 | 2023-02-07 | B |
| KFY | Korn Ferry | Q4 2022 | 2022-06-22 | B |
| ZVIA | Zevia PBC | Q1 2022 | 2022-05-12 | B |
| CNXC | Concentrix Corporation | Q1 2022 | 2022-03-30 | B |
| KD | Kyndryl Holdings, Inc. | Q4 2021 | 2022-03-01 | C+ |
| NGVT | Ingevity Corporation | Q4 2021 | 2022-02-25 | B |
| VNDA | Vanda Pharmaceuticals Inc. | Q4 2021 | 2022-02-23 | F |
| SLQT | SelectQuote, Inc. | Q2 2022 | 2022-02-07 | F |
| EXP | Eagle Materials Inc. | Q3 2022 | 2022-01-27 | B |
| LC | LendingClub Corporation | Q4 2021 | 2022-01-26 | A |
| SXC | SunCoke Energy, Inc. | Q3 2021 | 2021-11-01 | A |
| LPTH | LightPath Technologies, Inc. | Q4 2021 | 2021-09-09 | D |
| CRS | Carpenter Technology Corporation | Q4 2021 | 2021-08-01 | A |
| UMH | UMH Properties, Inc. | Q3 2018 | 2018-11-02 | C+ |
| AGIO | Agios Pharmaceuticals, Inc. | Q3 2018 | 2018-11-01 | C |
| CUBI | Customers Bancorp, Inc. | Q3 2018 | 2018-10-26 | C+ |
| LRN | Stride, Inc. | Q1 2019 | 2018-10-23 | B |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| TOUR | Tuniu Corporation | Q4 2017 | 2018-03-14 | D |
| HSTM | HealthStream, Inc. | Q3 2017 | 2017-10-24 | C |
| PSX | Phillips 66 | Q4 2016 | 2017-02-03 | C+ |
| AEHR | Aehr Test Systems | Q2 2017 | 2017-01-05 | F |
| NTCT | NetScout Systems, Inc. | Q2 2017 | 2016-10-27 | D |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
TGLS · Q2 2023 → YESThe question is about whether management conveys a new capability that they can now do something they couldn't do a year ago, that customers are paying for now, and it's still early. YES Management explicitly contrasts the new capability against the prior limitation: extra capacity now enables them to sell stand-alone architectural glass and aluminum framing products that were previously allocated to window production due to capacity constraints. This is a clear before/after step-change in the class of work they can accept and perform. Real customers are already paying for this new output: the transcript states they have a little bit more installation in stand-alone product sales the rest of the year, and they are now very well positioned to increasingly service large homebuilders’ customers as well as demand for the stand-alone aluminum and glass products, with the absorption of new capacity and ability to offer a wider range of solutions to customers described as positive overall.
TACT · Q4 2022 → YESThe question is: Does management convey that the company CAN NOW ACTUALLY DO SOMETHING that it COULD NOT DO ROUGHLY A YEAR AGO, and that REAL CUSTOMERS ARE ALREADY PAYING FOR THAT NEW CAPABILITY NOW, ...YES The transcript shows management describing a clear before/after step-change in casino and gaming printers: they could produce printers before, but now they have added a third line in Q3 and begun manufacturing on a fourth line in Q4, enabling them to meet demand and take market share that the prior competitor could not supply 12 months ago.
ZVIA · Q1 2022 → YESThe question is: Does management convey that the company CAN NOW ACTUALLY DO SOMETHING that it COULD NOT DO ROUGHLY A YEAR AGO, and that REAL CUSTOMERS ARE ALREADY PAYING FOR THAT NEW CAPABILITY NOW, ...YES Management describes the launch of single-serve 12-ounce cans as a first-time capability: “we began selling Zevia’s soda in single cans for the first time in a 12-ounce sleek format,” now “available cold in several grocery retailers” with “some of which is shipping now.